Variation in Medicare Part D topical steroid prescription costs - 16/03/23
Doi : 10.1016/j.jaad.2022.09.057
Adam Faletsky, MD, MBA a, b, Bina Kassamali, MD a, c, Jane J. Han, MD a, d, Bruce Zhao, PhD a, Avery LaChance, MD, MPH a, Arash Mostaghimi, MD, MPA a, ⁎ 
a Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts
b Tufts University School of Medicine, Boston, Massachusetts
c Harvard Medical School, Boston, Massachusetts
d Loyola Stritch School of Medicine, Maywood, Illinois
∗Correspondence and reprint requests to: Arash Mostaghimi, MD, MPA, Department of Dermatology, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115Department of DermatologyBrigham and Women's Hospital221 Longwood AveBostonMA02115
Key words : dermatology, drug costs, health equity, insurance, Medicare, out-of-pocket, PDP, prescription drug plan, topical steroids
| Previous presentations: Society for Investigative Dermatology Annual Meeting, May 5th, 2021. |
|
| Drs Faletsky, Kassamali and Han contributed equally to this article. |
|
| Drs LaChance and Mostaghimi are senior co-authors. |
|
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
|
| Patient consent forms: Not applicable. |
© 2022
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 88 - N° 4
P. 928-930 - avril 2023 Retour au numéro
Article précédent
- Dermatology Image Quality Assessment (DIQA): Artificial intelligence to ensure the clinical utility of images for remote consultations and clinical trials
- Ignacio Hernández Montilla, Taig Mac Carthy, Andy Aguilar, Alfonso Medela
- Complications in dermatologic surgery: A case-control study exploring factors associated with postsurgical infection and wound dehiscence in a large national group practice
- Tanner P. Harding, Nicole J. Levin, James A. Solomon
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?